IL70286A - Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them - Google Patents

Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them

Info

Publication number: IL70286A
Authority: IL; Israel
Prior art keywords: hydrogen; benzyloxy; phenoxy; trifluoromethyl; fluoro
Prior art date: 1982-11-22

Application number

IL70286A

Other languages

English (en)

Other versions

IL70286A0 (en

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-22

Filing date

1983-11-21

Publication date

1987-08-31

1983-11-21 Application filed by Sandoz Ag filed Critical Sandoz Ag

1984-02-29 Publication of IL70286A0 publication Critical patent/IL70286A0/xx

1987-08-31 Publication of IL70286A publication Critical patent/IL70286A/xx

Links

239000002253 acid Substances 0.000 title abstract 2
150000007513 acids Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 12
239000001257 hydrogen Substances 0.000 abstract 12
150000002431 hydrogen Chemical group 0.000 abstract 7
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
-1 t-butoxy Chemical group 0.000 abstract 6
125000001153 fluoro group Chemical group F* 0.000 abstract 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1
150000003839 salts Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Indole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Saccharide Compounds (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL70286A 1982-11-22 1983-11-21 Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them IL70286A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44366882A	1982-11-22	1982-11-22
US54885083A	1983-11-04	1983-11-04

Publications (2)

Publication Number	Publication Date
IL70286A0 IL70286A0 (en)	1984-02-29
IL70286A true IL70286A (en)	1987-08-31

Family

ID=27033614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL70286A IL70286A (en)	1982-11-22	1983-11-21	Omega-(1,3-disubstituted indol-2-yl-3,5-dihydroxy)alkanoic and-alkenoic acids and derivatives thereof,their production and pharmaceutical compositions containing them

Country Status (18)

Country	Link
EP (1)	EP0114027B1 (de)
JP (1)	JPH0347167A (de)
AT (1)	ATE31718T1 (de)
AU (1)	AU570021B2 (de)
CA (1)	CA1210405A (de)
CY (1)	CY1579A (de)
DE (2)	DE19475017I2 (de)
DK (2)	DK359284A (de)
FI (1)	FI77228C (de)
GR (1)	GR79042B (de)
HK (1)	HK11191A (de)
HU (1)	HU204253B (de)
IE (1)	IE56262B1 (de)
IL (1)	IL70286A (de)
LU (1)	LU88670I2 (de)
NL (1)	NL950022I2 (de)
NZ (1)	NZ206338A (de)
WO (1)	WO1984002131A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5354772A (en) *	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) *	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5001255A (en) *	1984-12-04	1991-03-19	Sandoz Pharm. Corp.	Idene analogs of mevalonolactone and derivatives thereof
HU198005B (en) *	1984-12-04	1989-07-28	Sandoz Ag	Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
AU598775B2 (en) *	1985-10-25	1990-07-05	Sandoz Ag	Heterocyclic analogs of mevalonolactone
US4851427A (en) *	1985-10-25	1989-07-25	Sandoz Pharm. Corp.	Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
NZ221717A (en) *	1986-09-10	1990-08-28	Sandoz Ltd	Azaindole and indolizine derivatives and pharmaceutical compositions
US4751235A (en) *	1986-12-23	1988-06-14	Sandoz Pharm. Corp.	Anti-atherosclerotic indolizine derivatives
US4735958A (en) *	1986-12-22	1988-04-05	Warner-Lambert Company	Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) *	1987-02-25	1990-02-06	Bristol-Myers Company	Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4894386A (en) *	1987-04-15	1990-01-16	Ici Americas Inc.	Aliphatic carboxamides
US4904646A (en) *	1987-05-22	1990-02-27	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) *	1987-05-22	1992-02-25	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
CA1336714C (en) *	1987-08-20	1995-08-15	Yoshihiro Fujikawa	Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5185328A (en) *	1987-08-20	1993-02-09	Nissan Chemical Industries Ltd.	Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
JP2569746B2 (ja) *	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
DE3739882A1 (de) *	1987-11-25	1989-06-08	Bayer Ag	Substituierte hydroxylamine
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
HU202842B (en) *	1988-01-27	1991-04-29	May & Baker Ltd	Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them
US4822799A (en) *	1988-01-27	1989-04-18	Sandoz Pharm. Corp.	Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) *	1988-02-25	1989-08-28	Bayer Ag	Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) *	1988-04-26	1991-06-18	Nissan Chemical Industries Ltd.	Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) *	1988-04-26	1999-05-17	日産化学工業株式会社	ピラゾロピリジン系メバロノラクトン類
US4870187A (en) *	1988-08-23	1989-09-26	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl compounds
US5010205A (en) *	1988-08-23	1991-04-23	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl intermediates
NZ230121A (en) *	1988-08-29	1993-08-26	Squibb & Sons Inc	Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
IL91941A (en) *	1988-10-13	1994-10-21	Sandoz Ag	Preparation of 6-Anoic and 7-Metanoic Fatty Acids and Their Substances and Intermediate Compounds and Acid 7-] 3-) 4-Fluorophenyl (-1-) 1- Methylethyl (a)
JPH04270285A (ja) *	1988-11-14	1992-09-25	Nissan Chem Ind Ltd	ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) *	1989-04-06	1990-10-11	Bayer Ag	Substituierte 1,8-naphthyridine
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) *	1989-08-22	1989-10-04	Fujisawa Pharmaceutical Co	Pyrroloquinoline compounds
IT1237792B (it) *	1989-12-21	1993-06-17	Zambon Spa	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE4243279A1 (de)	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
JP2736599B2 (ja) *	1993-07-23	1998-04-02	株式会社キッツ	ボールバルブのシート構造
DE19513716A1 (de) *	1995-02-01	1996-08-08	Bayer Ag	Substituierte 2-Phenylindol-Derivate
US6425881B1 (en)	1994-10-05	2002-07-30	Nitrosystems, Inc.	Therapeutic mixture useful in inhibiting lesion formation after vascular injury
DE69719755T2 (de) *	1996-06-24	2003-11-20	Novartis Ag, Basel	Polymorphe verbindungen
US7008950B1 (en)	1997-06-05	2006-03-07	Takeda Chemical Industries, Ltd.	Benzofurans as suppressors of neurodegeneration
SK288117B6 (sk)	1998-11-20	2013-09-03	Skyepharma Canada Inc.	Rapidly dispersing solid dry therapeutic dosage form
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
CN1217930C (zh)	2000-05-26	2005-09-07	西巴特殊化学品控股有限公司	吲哚衍生物的制备方法和该方法的中间体
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
EP1379259A1 (de)	2001-04-18	2004-01-14	Genzyme Corporation	Verfahren zur behandlung von syndrom x mit aliphatischen polyaminen
ES2304140T3 (es) *	2001-08-03	2008-09-16	Ciba Holding Inc.	Formas cristalinas de sodio de fluvastatina.
EP1465882B1 (de)	2001-12-21	2011-08-24	X-Ceptor Therapeutics, Inc.	Heterocyclische modulatoren von nukleären rezeptoren
EP1496897A4 (de)	2002-04-12	2006-05-10	Merck & Co Inc	Tyrosinkinase-hemmer
CN1839114A (zh)	2003-08-21	2006-09-27	默克弗罗斯特加拿大有限公司	组织蛋白酶半胱氨酸蛋白酶抑制剂
EP1510208A1 (de)	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
CN100404479C (zh) *	2003-08-27	2008-07-23	住友化学株式会社	芳族不饱和化合物的制备方法
US8227434B1 (en)	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
WO2006062876A2 (en) *	2004-12-09	2006-06-15	Merck & Co., Inc.	Estrogen receptor modulators
US7709508B2 (en)	2004-12-09	2010-05-04	Merck Sharp & Dohme	Estrogen receptor modulators
AU2006302797B2 (en)	2005-03-02	2012-02-02	Merck Canada Inc.	Composition for inhibition of cathepsin K
KR101363278B1 (ko)	2005-06-27	2014-02-21	엑셀리시스 페이턴트 컴퍼니 엘엘씨	이미다졸계 ｌｘｒ 변조제
WO2007017117A1 (en) *	2005-07-28	2007-02-15	Lek Pharmaceuticals D.D.	Process for the synthesis of rosuvastatin calcium
PE20070335A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Benzimidazoles sustituidos y metodos para su preparacion
US8440695B2 (en)	2005-11-09	2013-05-14	St Jude Children's Research Hospital	Use of chloroquine to treat metabolic syndrome
KR101464385B1 (ko)	2006-04-19	2014-11-21	노파르티스 아게	６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
ATE431818T1 (de)	2006-04-20	2009-06-15	Italiana Sint Spa	Verfahren zur herstellung von fluvastatin-natrium
PT2359826E (pt)	2006-07-05	2014-01-20	Takeda Gmbh	Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101679266B (zh)	2007-03-01	2015-05-06	诺华股份有限公司	Pim激酶抑制剂及其应用方法
AU2008254425A1 (en)	2007-05-21	2008-11-27	Novartis Ag	CSF-1R inhibitors, compositions, and methods of use
ES2330184B1 (es)	2008-06-03	2010-07-05	Neuron Biopharma, S.A.	Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (de)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte.
WO2010069593A1 (en)	2008-12-19	2010-06-24	Krka, D. D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
MY153958A (en)	2009-05-28	2015-04-30	Exelixis Patent Co Llc	Lxr modulators
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
EP2937345B1 (de)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Typ-ii-raf-kinase-hemmer
BR112012023021A2 (pt)	2010-03-16	2016-05-31	Dana Farber Cancer Inst Inc	compostos de indazol e seus usos
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
US20130210860A1 (en)	2010-10-06	2013-08-15	Kowa Co., Ltd.	Prophylactic and/or therapeutic agent against lymphedema
EP2675440B1 (de)	2011-02-14	2020-03-25	Merck Sharp & Dohme Corp.	Cathepsin-cysteinproteasehemmer
TW201242953A (en)	2011-03-25	2012-11-01	Bristol Myers Squibb Co	Imidazole prodrug LXR modulators
JP6106685B2 (ja)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
CA2865796A1 (en)	2011-12-29	2013-07-04	Trustees Of Tufts College	Functionalization of biomaterials to control regeneration and inflammation responses
EP2909194A1 (de)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Hemmer der cyclinabhängigen kinase 7 (cdk7)
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
JP6442475B2 (ja)	2013-03-15	2018-12-19	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｌｘｒ調節因子
EP2810644A1 (de)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
RU2692799C2 (ru)	2013-10-08	2019-06-27	Мерк Шарп И Доум Корп.	Ингибиторы цистеинпротеаз катепсинов
WO2015051479A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015120580A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
EP3810132A4 (de)	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	Kinaseinhibitoren der taire und ihre verwendungen
CN113164477A (zh)	2018-12-14	2021-07-23	达纳-法伯癌症研究所股份有限公司	C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (de)	2018-12-28	2022-09-07	Dana-Farber Cancer Institute, Inc.	Hemmer der cyclinabhängigen kinase 7 und verwendungen davon

1983
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/de not_active Ceased
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 EP EP83810548A patent/EP0114027B1/de not_active Expired
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 CA CA000441684A patent/CA1210405A/en not_active Expired
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284A/da not_active Application Discontinuation
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/en not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown

Also Published As

Publication number	Publication date
NZ206338A (en)	1987-08-31
HUT35642A (en)	1985-07-29
EP0114027A1 (de)	1984-07-25
ATE31718T1 (de)	1988-01-15
DK359284D0 (da)	1984-07-20
IE832713L (en)	1984-05-22
DK97890A (da)	1990-04-19
NL950022I2 (nl)	1996-12-02
LU88670I2 (fr)	1996-04-29
IE56262B1 (en)	1991-06-05
DK165244C (da)	1993-03-22
JPH0440343B2 (de)	1992-07-02
WO1984002131A1 (fr)	1984-06-07
DE3375137D1 (en)	1988-02-11
HK11191A (en)	1991-02-13
AU570021B2 (en)	1988-03-03
FI77228C (fi)	1989-02-10
GR79042B (de)	1984-10-02
DK97890D0 (da)	1990-04-19
DK165244B (da)	1992-10-26
HU204253B (en)	1991-12-30
CA1210405A (en)	1986-08-26
IL70286A0 (en)	1984-02-29
EP0114027B1 (de)	1988-01-07
DE19475017I2 (de)	2003-02-20
FI842615A7 (fi)	1984-06-28
FI77228B (fi)	1988-10-31
CY1579A (en)	1991-12-20
NL950022I1 (de)	1996-01-02
FI842615A0 (fi)	1984-06-28
JPH0347167A (ja)	1991-02-28
AU2261283A (en)	1984-06-18
DK359284A (da)	1984-07-20

Legal Events

Date	Code	Title
1997-11-20	HC	Change of name of proprietor(s)
1998-04-05	KB	Patent renewed
2002-02-10	KB	Patent renewed
2004-02-08	EXP	Patent expired

Publication	Publication Date	Title
AU570021B2 (en)	1988-03-03	Analogs of mevalolactone
AU570942B2 (en)	1988-03-31	Analogs of mevalonolactone and derivatives thereof, processesfor their production, pharmaceutical compositions containing them and their use as pharmaceuticals
DE3460035D1 (en)	1986-04-03	1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and formulations containing it
MY105158A (en)	1994-08-30	Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors.
FI895046A0 (fi)	1989-10-24	4-amino-3-acylkinolinderivat samt deras anvaendning saosom inhibitorer av sekretion av matsmaeltningsvaetskor.
DE3067201D1 (en)	1984-04-26	Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them
IL75116A (en)	1989-10-31	Ethyl substituted-beta-carboxylates,process for the preparation thereof and pharmaceutical compositions containing the same
GB2160525A (en)	1985-12-24	8,10-dideazaminopterins
PT76693B (en)	1986-08-28	(-)-15-deoxyspergualin a process for the preparation of the same an intermediate of the same and its use as medicament
IL61769A0 (en)	1981-01-30	2-phenylamino-imidazolines-(2),their preparation and pharmaceutical compositions containing them
ES8506660A1 (es)	1985-08-01	Un procedimiento para la preparacion de un compuesto de b-lactama